Search
Elexacaftor
go.drugbank.com/drugs/DB15444ApprovedInvestigational[L9395] Elexacaftor is considered a next-generation CFTR corrector as it possesses both a different structure and mechanism as compared to first generation correctors like tezacaftor. … [A187361] Elexacaftor, along with [VX-659], was designed to fill the need for an efficacious CF therapy for patients who are heterozygous for _F508del-CFTR_ and a gene that does not produce protein or
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 SubstratesDuvelisib
go.drugbank.com/drugs/DB11952ApprovedInvestigationalcan produce a broad adaptative and innate immune cell inhibitory activity. … Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesDe Novo Triacylglycerol Biosynthesis TG(15:0/24:1(15Z)/18:3(9Z,12Z,15Z))
smpdb.ca/view/SMP0017298MetabolicA triglyceride (TG, triacylglycerol, TAG, or triacylglyceride) is an ester derived from glycerol and three fatty acids. Triglycerides are the main constituents of body fat in humans and other animals, as well as vegetable fat. They are a...
De Novo Triacylglycerol Biosynthesis TG(15:0/18:3(9Z,12Z,15Z)/24:1(15Z))
smpdb.ca/view/SMP0017471MetabolicA triglyceride (TG, triacylglycerol, TAG, or triacylglyceride) is an ester derived from glycerol and three fatty acids. Triglycerides are the main constituents of body fat in humans and other animals, as well as vegetable fat. They are a...
Maftivimab
go.drugbank.com/drugs/DB15899ApprovedInvestigational[A221825] Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and high … Ebola virus (EBOV) remains an important human pathogen within the _Ebolavirus_ genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%.
Ademetionine
go.drugbank.com/drugs/DB00118ApprovedInvestigationalNutraceuticalPhysiologic methyl radical donor involved in enzymatic transmethylation reactions and present in all living organisms. It possesses anti-inflammatory activity and has been used in treatment of chronic liver disease. (From Merck, 11th ed)
Mixtures: HEPATAMINE %8 500 ML(SETLI), HEPATAMINE %8 500 ML(SETSIZ)Categories: Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 Enzyme InhibitorsCupric Chloride
go.drugbank.com/drugs/DB09131ApprovedCupric chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN).
Mixtures: TRACUTIL® 10 ML AMPOLLASLumasiran
go.drugbank.com/drugs/DB15935ApprovedInvestigational[L23554] This condition, caused by a deficiency in the enzyme alanine-glyoxylate aminotransferase, leads to an accumulation of oxalate, causing calcium crystal formation. … Lumasiran is a small interfering RNA used in the treatment of primary hyperoxaluria type 1 (PH1).
Categories: Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 Enzyme InhibitorsIC41
go.drugbank.com/drugs/DB05776InvestigationalIC41 is a therapeutic peptide vaccine. It is being devloped by Intercell AG for the treatment of hepatitis C.
Concizumab
go.drugbank.com/drugs/DB12820ApprovedInvestigationalConcizumab is a humanized IgG4 monoclonal antibody targeting the Kunitz-2 domain of tissue factor pathway inhibitor (TFPI), a key regulator of the coagulation cascade. … [L52043] Concizumab-mtci (Alhemo) was approved by the FDA in December 2024 for use in patients with hemophilia A or B with inhibitors.